After the protocol-related indecisive clinical trial of Oxygent, a perfluorooctylbromide/
phospholipid nanoemulsion, in cardiac surgery, that often unduly assigned the observed …

Phase change contrast agents (PCCAs) have been studied in the medical ultrasound field
for nearly three decades. Their ability to convert from a liquid core droplet to an acoustically …

Localization-based ultrasound super-resolution imaging using microbubble contrast agents
and phase-change nanodroplets has been developed to visualize microvascular structures …

Ultrasound Contrast Agents (UCAs) consisting of gas-filled-coated Microbubbles (MBs) with
diameters between 1 and 10 µm have been used for a number of decades in diagnostic …

Microbubble (MB) contrast agents have positively impacted the clinical ultrasound (US)
community worldwide. Their use in molecular US imaging applications has been hindered …

Ultrasound molecular imaging has been developed in the past two decades with the goal of
non-invasively imaging disease phenotypes on a cellular level not depicted on anatomic …

Contrast ultrasound has a variety of applications in cardiovascular medicine, both in
diagnosing cardiovascular disease as well as providing prognostic information …

Phase-change contrast agents (PCCAs) possess advantages over microbubble contrast
agents, such as the ability to extravasate and circulate longer in the vasculature that could …

Phase-change ultrasound contrast agent (PCCA), or nanodroplet, shows promise as an
alternative to the conventional microbubble agent over a wide range of diagnostic …

Type 1 diabetes (T1D) results from immune infiltration and destruction of insulin-producing β
cells within the pancreatic islets of Langerhans (insulitis). Early diagnosis during …